Metabolon’s diagnostics team is working to create metabolomics-driven diagnostic tests that give healthcare providers actionable information to aid in patient management.
We currently have two laboratory-developed tests (LDTs) that are run in our Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited clinical laboratory:
- Quantose IR™ is Metabolon’s first commercially available laboratory test for obesity-related chronic diseases. It assesses the level of insulin resistance and provides treatment monitoring for prediabetes. Clinical intervention at this stage of disease could help delay or prevent the onset of type 2 diabetes. Quantose IR is currently available in the U.S., Mexico and Europe.
- Quantose IGT™ reflects the degree of impaired glucose tolerance in an individual. Impaired glucose tolerance (IGT) is a known risk factor for prediabetes. Our test is designed to easily differentiate IGT from normal glucose tolerance with only a single, fasted blood draw.
Looking forward, Metabolon is focused on developing and delivering additional diagnostic and prognostic tools for obesity-related chronic diseases and potentially many other clinical areas. We are currently developing tests for:
- Liver disease (NASH)
- Kidney function (GFR)
We believe that our pipeline diagnostic products could eventually become important clinical tools for the early detection of diseases and provide information that may help health care providers better manage their patients' care.
All of our clinical diagnostic tests and pipeline products are developed using Metabolon’s proprietary metabolomics technology. Our global metabolomics screening technology, the DiscoveryHD4™ platform, enables the rapid discovery of clinically relevant metabolite biomarkers and their efficient translation into clinical practice. This technology holds the potential to accelerate the discovery and development of novel laboratory tests that may advance the management of some major human diseases.